Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,054

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside

Alzahrani, Ali S.·2019·Seminars in Cancer Biology

Abstract

Phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway is one of the major cellular signaling pathways play an important role in basic intracellular functions. The PI3K/Akt/mTOR pathway regulates cell proliferation, growth, cell size, metabolism, and motility. Component genes of this pathway were extensively studied and found to be commonly activated in human cancer. Inhibition of this pathway is shown to have better regression of human tumors and being studied in preclinical and evaluated in many clinical trials at various levels. Some inhibitors of this pathway are approved by the food and drug administration after their potent activity and their effect overweighed the toxicities/side effects. This review discusses the recent trends in exploiting the PI3K/Akt/mTOR pathway towards the molecular targeted therapy using small molecule inhibitors in human cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.semcancer.2019.07.009

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 1,054

Metadata

Authors
Alzahrani, A. S.
Venue
Seminars in Cancer Biology
Publisher
Elsevier BV
Published
2019-12
Volume
59
Pages
125-132
ISSN
1044-579X (ISSN-L)
OpenAlex
W2962354828
Cited by
1,054
References
6
FWCI
31.15
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside. https://app.cochat.ai/papers/10.1016/j.semcancer.2019.07.009
The paper
Alzahrani, A. S. (2019). PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside. Seminars in Cancer Biology. https://doi.org/10.1016/j.semcancer.2019.07.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.